About Careers Internship MedBlog Contact us

Experimental Alzheimer's Drug Slows Disease Progress in Early Study

by Bidita Debnath on March 21, 2015 at 11:21 PM
Experimental Alzheimer's Drug Slows Disease Progress in Early Study

In an early study, a new experimental drug for Alzheimer's disease has already exceeded high expectations.

The results of the trial of an antibody known as aducanumab, have shown some benefit in people who were given it in the very earliest stage of the disease, the Guardian reported. In the trial, conducted primarily to ensure the drug was safe and had no serious side-effects, brain scans showed a reduction of amyloid plaque, whose accumulation is thought to be one of the major causes of Alzheimer's.


The higher the dose of drug the patient was given, the greater the reduction and tests also showed that those people who took the drug had a slower rate of mental decline than those who did not.

Eric Karran, director of research at Alzheimer's Research UK, said that these are very promising early results, which not only demonstrate the safety of this treatment, but also suggest it may hold benefits in the early stages of Alzheimer's disease.

Karran added that while many previous anti-amyloid therapies have failed to meet their goals, these preliminary findings back up research suggesting that treatments targeting amyloid will need to be given early in the disease.

Karran noted that further data from this trial is yet to be reported, and it will be important to see this data as well as results from much larger trials before we can understand how effective this treatment may be.

Alfred Sandrock, group senior vice-president and chief medical officer at Biogen Idec, the company that made the drug, announced it would be moving quickly into large-scale trials which will involve hundreds, if not thousands, of people.

The trial results were presented at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Nice, France.

Source: ANI
Font : A-A+



Recommended Readings

Latest Drug News

Projected Growth: Psychedelic Drug Market Anticipated to Hit $7.2 Billion by 2029
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
Promising ALS Drug Candidate Extends Lifespan
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-Calvulanate Vs Amoxicillin Preference in Child Sinusitis Treatment
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
ADHD Medication Errors Surge by Nearly 300%
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
Unknown Medication Side Effects Reported by 52% of Indian Families
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

Experimental Alzheimer's Drug Slows Disease Progress in Early Study Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests